HOME >> BIOLOGY >> NEWS
Eastern Europe urged to prepare now for growing threat of HIV resistance

Eastern Europe is warned to prepare for HIV drug resistance, a problem that is now being witnessed in patients in Poland after only five years of HIV treatment being available. Experts at an HIV congress in Warsaw heard today that FUZEON (enfuvirtide, formerly known as T-20), the latest weapon in the fight against HIV drug resistance, is a valuable tool to both patients and payers in the treatment of HIV, particularly when used earlier in pre-treated patients.

Eastern Europe urged to prepare for HIV resistance

John Bowis, OBE, Member of the European Parliament applauds the Ministry of Health in Poland for taking a pro-active lead in the fight against HIV and drug resistance: "The growing problem of HIV resistance is a serious issue which all members of the EU have a responsibility to manage. We must commit to share knowledge, particularly those countries more experienced in tackling the HIV epidemic, in an effort to provide a consistent standard of care and avert a potential healthcare crisis. We need to ensure that all European countries are benefiting from new treatments and are allocating vital resources where they will be of most value."

The increasing prevalence of HIV drug resistance means that many patients can no longer benefit from the first three classes of HIV drugs. Unlike existing anti-HIV drugs, which act inside the cell once it has been infected, FUZEON works on the outside actively blocking the fusion of the virus with cells of the human immune system (CD4 cells). Because of this very different mechanism of action, FUZEON is active against HIV strains that have become resistant to current therapies. FUZEON reduces HIV levels and increases CD4 cell counts even in patients with resistance to the three conventional classes of HIV drugs.

Improving survival in pre-treated patients carrying drug-resistant HIV

Reduction in HIV levels and improvements in CD4 cell counts have been shown to result in improved s
'"/>

Contact: Alexander Watson
Alexander.watson@ketchum.com
44-771-267-5990
Ketchum
27-Oct-2003


Page: 1 2 3

Related biology news :

1. Eastern lowland gorilla population plummets 70 percent since 1994
2. Eastern U.S. benefits from emissions trading by power plants
3. Environment in Eastern Europe benefits from Swedish funding
4. USGS Finds That Mysterious Arkansas Bald Eagle Disease Has Spread To Ducks In Eastern States
5. Clean Air Act Reduces Acid Rain In Eastern U.S.
6. Even Moderate Air Pollution Reaching Eastern Wilderness Decreases Mountain Hikers Lung Function
7. European common frog found to use novel mating strategy
8. Zoonotic diseases - European scientists unite to fight diseases
9. Second call for proposals for the European Young Investigator Award
10. Common call for action on European Research Council (ERC)
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Eastern Europe urged prepare now for growing threat HIV resistance

(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
(Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:9/2/2015)... , Sep. 02, 2015 ... ) has announced the addition of Jain ... Markets and Companies" to their offering. ... several technologies besides fluorescence in situ hybridization ... FISH. Molecular cytogenetics includes application of nanobiotechnology, ...
(Date:9/2/2015)... Sept. 2, 2015 Australian prostate cancer technology ... Australian science prize recognising ,outstanding, science that uses its ... globally launch a novel prostate cancer diagnostic test known ... level consortium taking out the peer-reviewed Australian Museum Eureka ... This prize is awarded for ground ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's ... entire waste to energy process and continue to contribute to the sustainability of ... Temarry’s Waste to Energy process has been operating at their Mexico facility, Recicladora ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
Cached News: